Onconetix, Inc.

ONCO

US09610B1089

Pharmaceuticals

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-07-04 pm EDT			5-day change	1st Jan Change
0.1561 ^USD	-2.25%		-6.64%	-21.16%

Jun. 14	Onconetix, Inc. Announces the Appointment of Karina M. Fedasz as Interim Chief Financial Officer	CI
May. 20	Tranche Update on Onconetix, Inc.'s Equity Buyback Plan announced on November 10, 2022.	CI

Onconetix, Inc. Announces the Appointment of Karina M. Fedasz as Interim Chief Financial Officer

June 14, 2024 at 05:09 pm EDT

On June 13, 2024, Onconetix, Inc. announced the appointment of Karina M. Fedasz as the Company?s Interim Chief Financial Officer, effective June 10, 2024.

Latest news about Onconetix, Inc.

Onconetix, Inc. Announces the Appointment of Karina M. Fedasz as Interim Chief Financial Officer	Jun. 14	CI
Tranche Update on Onconetix, Inc.'s Equity Buyback Plan announced on November 10, 2022.	May. 20	CI
Onconetix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 20	CI
Tranche Update on Onconetix, Inc.'s Equity Buyback Plan announced on November 10, 2022.	Apr. 11	CI
Onconetix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 11	CI
Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors	Feb. 13	CI
Onconetix, Inc. Appoints Thomas Meier to the Board of Directors	Feb. 12	CI
Wall Street Set to Open Marginally Lower Friday; December Inflation Data Lower Than Forecast	Jan. 26	MT
US Futures Nudge Lower in Friday's Premarket Ahead of Fed Inflation Data	Jan. 26	MT
Onconetix, Inc. announced that it has received $5 million in funding	Jan. 22	CI
Onconetix, Inc. Announces Chief Executive Officer Changes	Jan. 12	CI
Onconetix, Inc. Announces Executive Changes	Jan. 12	CI
Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer	Dec. 28	CI
Onconetix, Inc.(NasdaqCM:ONCO) added to NASDAQ Composite Index	Dec. 26	CI
Onconetix, Inc. Announces Executive Appointments	Dec. 21	CI
Onconetix, Inc.(NasdaqCM:ONCO) dropped from NASDAQ Composite Index	Dec. 21	CI
Blue Water Biotech, Inc. acquired ProteoMediX AG for $51.9 million.	Dec. 20	CI
Blue Water Biotech, Inc has Changed its Name to Onconetix, Inc	Dec. 15	CI
Tranche Update on Blue Water Biotech, Inc.'s Equity Buyback Plan announced on November 10, 2022.	Nov. 17	CI
Blue Water Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17	CI
Tranche Update on Blue Water Biotech, Inc.'s Equity Buyback Plan announced on November 10, 2022.	23-10-20	CI
Blue Water Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-10-20	CI
Blue Water Biotech, Inc. Appoints Bruce Harmon as CFO	23-10-10	CI
Blue Water Biotech, Inc. Appoints Dr. Neil J. Campbell as CEO	23-10-10	CI
Blue Water Biotech, Inc. Appoints Dr. Neil J. Campbell as President	23-10-10	CI

Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5Î±-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patientâs regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.

Sector

Pharmaceuticals

More about the company

	1st Jan change	Capi.
ONCONETIX, INC.	-21.16%	3.49M
CSL LIMITED	+4.57%	97.7B
SAMSUNG BIOLOGICS CO.,LTD.	+5.66%	41.43B
BIOGEN INC.	-12.80%	32.85B
UCB	+80.99%	29.33B
BIOMARIN PHARMACEUTICAL INC.	-15.53%	15.47B
INCYTE CORPORATION	-8.70%	12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.22%	11.51B
ALTEOGEN INC.	+183.25%	10.74B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-55.41%	8.97B

Biopharmaceuticals

Onconetix, Inc.

Equities

ONCO

US09610B1089

Pharmaceuticals

Onconetix, Inc. Announces the Appointment of Karina M. Fedasz as Interim Chief Financial Officer

Latest news about Onconetix, Inc.

Chart Onconetix, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals